<p>|Recommendations|Certainty of evidence|Evidence report(s) of the following PICO(s)|Supp. App. 2|
|---|---|---|---|
|Subcutaneous nodules| | | |
|Methotrexate is conditionally recommended over alternative DMARDs for patients with subcutaneous nodules who have moderate-to-high disease activity.|Very low|PICO 64|p. 427|